KR20140103122A - 신경교종을 치료하기 위한 조성물 및 방법 - Google Patents

신경교종을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20140103122A
KR20140103122A KR1020147016562A KR20147016562A KR20140103122A KR 20140103122 A KR20140103122 A KR 20140103122A KR 1020147016562 A KR1020147016562 A KR 1020147016562A KR 20147016562 A KR20147016562 A KR 20147016562A KR 20140103122 A KR20140103122 A KR 20140103122A
Authority
KR
South Korea
Prior art keywords
peptide
glioma
csf
seq
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147016562A
Other languages
English (en)
Korean (ko)
Inventor
보제나 카민스카-카츠마렉
말고르자타 시엘스카
파벨 비스니에프스키
알렉산드라 엘레르트-미클라셰프스카
Original Assignee
넨키 인스티튜트 오브 익스페리멘탈 바이올로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 filed Critical 넨키 인스티튜트 오브 익스페리멘탈 바이올로지
Publication of KR20140103122A publication Critical patent/KR20140103122A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020147016562A 2011-11-17 2012-11-18 신경교종을 치료하기 위한 조성물 및 방법 Ceased KR20140103122A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161561080P 2011-11-17 2011-11-17
US61/561,080 2011-11-17
US201261583745P 2012-01-06 2012-01-06
US61/583,745 2012-01-06
PCT/IB2012/056533 WO2013072901A2 (en) 2011-11-17 2012-11-18 Compositions and methods for treating glioma

Publications (1)

Publication Number Publication Date
KR20140103122A true KR20140103122A (ko) 2014-08-25

Family

ID=47358252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016562A Ceased KR20140103122A (ko) 2011-11-17 2012-11-18 신경교종을 치료하기 위한 조성물 및 방법

Country Status (7)

Country Link
US (2) US9453050B2 (https=)
EP (1) EP2780363B1 (https=)
JP (1) JP6426001B2 (https=)
KR (1) KR20140103122A (https=)
CA (1) CA2856329A1 (https=)
IL (1) IL232648B (https=)
WO (1) WO2013072901A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220025115A (ko) * 2014-09-26 2022-03-03 내셔널 유니버시티 오브 싱가포르 Th-gm 세포 기능 조절 방법 및 조성물
WO2024155124A1 (ko) * 2023-01-20 2024-07-25 (주)넥셀 치주염 및 임플란트 주변염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 치주염 및 임플란트 주변염 예방 또는 치료용 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
US11078264B2 (en) * 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
US12582695B2 (en) * 2018-11-28 2026-03-24 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Compositions and methods for treating glioma
CN112007142B (zh) * 2019-05-31 2025-04-22 生物蚕茧研究所股份有限公司 向抗炎m2表型小胶质细胞的极性转化促进剂
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
CN116650650A (zh) * 2023-06-12 2023-08-29 郑州大学 一种抑制食管鳞癌中肿瘤相关巨噬细胞浸润的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0482086A1 (en) * 1989-07-14 1992-04-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
EP0486572B1 (en) * 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
AU756916B2 (en) 1998-11-12 2003-01-23 Jcr Pharmaceuticals Co., Ltd. Modulation of cell proliferative disorders by cyclic RGD
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
AU2592600A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
ATE507295T1 (de) * 2000-03-30 2011-05-15 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2003276828A1 (en) * 2002-05-10 2004-03-11 Children's Medical Center Corporation Minicell display and products therefrom
DE602006017806D1 (de) * 2005-02-18 2010-12-09 Proximagen Ltd Behandlung von neurodegeneration
EP2385061A3 (en) * 2005-05-10 2012-02-22 Neoloch Aps Neuritogenic peptides
CA2663749A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
MX2008012291A (es) * 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
DK2121586T3 (en) 2007-03-09 2017-06-19 Pathologica Llc MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS
DK2201138T3 (en) 2007-10-16 2015-05-18 Ventana Med Syst Inc GRADING, STAGE DETERMINATION AND FORECAST OF CANCER USING osteopontin-C
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
KR20110086757A (ko) 2008-11-20 2011-07-29 메르크 파텐트 게엠베하 암을 치료하기 위해 인테그린 리간드를 사용하는 신규한 치료요법 및 약제
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220025115A (ko) * 2014-09-26 2022-03-03 내셔널 유니버시티 오브 싱가포르 Th-gm 세포 기능 조절 방법 및 조성물
WO2024155124A1 (ko) * 2023-01-20 2024-07-25 (주)넥셀 치주염 및 임플란트 주변염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 치주염 및 임플란트 주변염 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP2780363A2 (en) 2014-09-24
US9453050B2 (en) 2016-09-27
US20140256628A1 (en) 2014-09-11
WO2013072901A3 (en) 2013-07-25
IL232648B (en) 2021-12-01
IL232648A0 (en) 2014-06-30
CA2856329A1 (en) 2013-05-23
EP2780363B1 (en) 2019-07-03
US20170035851A1 (en) 2017-02-09
WO2013072901A2 (en) 2013-05-23
JP2014533681A (ja) 2014-12-15
JP6426001B2 (ja) 2018-11-21

Similar Documents

Publication Publication Date Title
KR20140103122A (ko) 신경교종을 치료하기 위한 조성물 및 방법
EP2513146B1 (en) Antibodies against ror1 capable of inducing cell death of cll
EP3428186A1 (en) Treatment of fibrosis of the liver with antibodies which prevent il-11:il-11ralpha interaction
US20130273057A1 (en) Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US20210277102A1 (en) Compositions and methods for treating a tumor suppressor deficient cancer
KR20200100866A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
JP2011256179A (ja) 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
WO2011066284A1 (en) Methods and compositions for the treatment of immune disorders
KR20150122786A (ko) 암 전이의 진단, 예후 및 치료를 위한 방법
CN102348796B (zh) 新型癌抗原eEF2
KR20130107203A (ko) 섬유증의 검출 및 치료
Li et al. Pathogenic Tconvs promote inflammatory macrophage polarization through GM‐CSF and exacerbate abdominal aortic aneurysm formation
WO2012176175A1 (en) New uses of nanog inhibitors and related methods
CN106029101A (zh) 生物材料和其治疗用途
JP2015522251A (ja) 治療用のチオレドキシン相互作用タンパク質（ｔｘｎｉｐ）のインヒビター
CN106177953A (zh) Tlr3抑制剂在制备防治肿瘤转移产品中的应用
US20240307531A1 (en) Compositions and methods of treating sarcoma lung metastasis
US20250388639A1 (en) Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182)
EP3468564A1 (en) Methods for diagnosing and treating metastatic cancer
EP2575883B1 (en) Treatment of inflammatory disorders
US11155820B2 (en) Target of VGSC β3 protein for prevention, treatment and diagnostic detection of cancers
WO2023183822A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
JP2024511569A (ja) 免疫増強剤
US9150929B2 (en) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
DK2257299T3 (en) Modulation of SRPX2-mediated angiogenesis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150327

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171108

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190827

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200611

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190827

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I